Mass Spectromety seems to be the best way to look for biomarkers. Here's an article indicating that Mass Spectrometry in Biomarker Research to Exceed $745 Million by 2010. The article links to a Market Research report. The report costs $3k but the table of contents is accessible after signing up. There is only 1 bullet on aging but overall the TOC alone provides some insight into the market concepts, terms, companies and products.
Chapter One: Executive Summary
* Proteomics Tools, Approaches in Drug Discovery, Biomarker Discovery
* Biomarker Validation, Diagnostics, Prognostics
* Sources of Samples
* Biomarkers in Pharmaceutical Industry, Diagnostics Industry
* Drug Discovery and Development
* Diagnostics
* Scope and Outline
* Market Summary
Chapter Two: Introduction
* Historical Background
* Definitions
o Biomarkers
o Screening Markers
o Prognostic Markers
o Staging Markers
o Stratification Markers
o Efficacy Markers
o Target Markers
o Toxicity Markers
o Antecedent Markers
o Translation Markers
o Surrogate Markers
o Positive Predictive Value (PPV)
o Sensitivity
o Specificity
* Value of Biomarkers in Industry
* Mass Spectrometry in Proteomics
o Software
o Tandem Mass Spectrometry
o Types of Mass Spectrometers Used for Protein Biomarkers
o MALDI-TOF
o TOF / TOF
o Triple Quad
o Quadrupole TOF
o Quadrupole Ion Trap
o Fourier Transform MS (FTMS / FT-ICR-MS)
* Biomarker Discovery
o MS in Biomarker Applications
o Biomarker Discovery Process in Diagnostics
o Biomarker Discovery in Drug Development
* Biomarker Validation
o Validation Process in Drug Discovery and Development
o Validation Process in Diagnostics
Chapter Three: Disease Application Areas
* Cancer
o Prostate
o Prostate Cancer Related Articles:
o Breast
o Breast Cancer Related Articles:
o Lung
o Ovarian / Endometrial
o Ovarian Cancer Related Articles:
o Oral / Lymphoma
o Oral Cancer Related Articles:
o Liver
o Other / Multiple Cancers
o General Cancer Related Articles:
* Cardiovascular Disease
* Neurological Disease
o Parkinson’s Disease
o Alcohol Abuse
o Sleep Apnea
o Cerebral Injury
o Amyotrophic Lateral Sclerosis (ALS)
* Diabetes
* Aging
o Aging Related Articles:
* Sepsis
Chapter Four: Proteomics Tools
* Introduction
* 2D Gel Electrophoresis (2DGE)
* Recent Developments in 2DGE
* Liquid Chromatography (LC)
* Recent Developments in LC
* Protein Chips
Chapter Five: Trends
* Industry Trends
o MS Vendors Creating Biomarker Divisions, Collaborations
o Some Acquisition, Consolidation Trends in Recent Years
o Regulatory Environment Becoming More Clearly Defined
o Drug Companies’ Woes Bringing Growth in Biomarkers
o Intellectual Property Defines Companies’ and Instruments’ Territories
o Diagnostics Industry Facing Uncertain IP Issues
o Globalization and Diversity Converging Rapidly
o Technology Trends
+ Ongoing Debate, Confusion Over Protein Patterns Vs Identified Markers
+ Emphasis on Sample Preparation, Fractionation
+ High Abundance, Low Abundance, Both
+ LC and ESI Approaches Growing Relative To 2DGE and MALDI
+ New Combinations of LC, ESI, and MALDI
+ Integration and Automation
+ Advances in Labels to Address Focused Applications
+ Biomarkers for Classes of Drugs
+ Chemogenomics / Chemoproteomics Techniques Further Driving Advances
+ Direct Analysis of Tissue
+ Shift to Solid-State Lasers
+ Field Applications Driving Miniaturization
Chapter Six: MS Software Market
* Products and Competitors
o Agilent Technologies
o GeneSpring MS
o MassHunter
o SpectrumMill
o Applied Biosystems / MDS Sciex
o Analyst
o MarkerView
o Pro QUANT
o ProteinPilot
o Bruker Biosciences
o ClinProTools
o flexImaging
o Cerno Biosciences
o MassWorks
o Correlogic Systems
o Proteome Quest
o GeneData AG
o Expressionist Pro
o GenoLogics Life Sciences Software
o Proteus
o Insightful Corp
o S+Proteome
o Genstruct
o Molecular Epistemics platform
o Matrix Science
o Mascot
o Nonlinear Dynamics
o Progenesis PG600
o Thermo
o SIEVE
o Public Domain Tools and Databases
* Revenue and Growth Forecast
Chapter Seven: MS Services Market
* Competitors
o BG Medicine
o Biophysical Corporation
o Caprion Pharmaceuticals
o Celera Diagnostics
o Compugen
o Panatecs
o Power3 Medical Products
o Predictive Diagnostics
o Protein Discovery, Inc
o RxGen PrimaTox
o SurroMed
* Revenue and Growth Forecast
Chapter Eight: MS Instrumentation Market
* Products
o Agilent Technologies (Palo Alto, CA)
o Agilent 1200 Series HPLC-Chip/MS System
o Agilent 3100 OFFGEL Fractionator
o Agilent 6210 TOF
o Agilent 6340 Ion Trap Liquid Chromatograph/Mass Spectrometer (LC/MS)
o Agilent 6510 Q-TOF LC/MS
o Multiple Affinity Removal System 7 LC Column and Spin Tube
o Applied Biosystems / MDS Sciex (Foster City, CA ; Ontario, Canada)
o 3200 Q TRAP LC/MS/MS System for Proteomics Applications
o 4000 Q TRAP LC/MS/MS System for Proteomics Applications
o 4800 MALDI-TOF/TOF
o ICAT Reagents
o iTRAQ Reagents
o QSTAR Elite LC/MS/MS
o MIDAS TRAQ Systems
o Becton Dickinson (Franklin Lakes, NJ)
o P100 Sample Collection Tubes
o Beckman Coulter (Fullerton, CA)
o ProteomeLab IgY-12 Partitioning Chemistries
o Bruker Biosciences (Billerica, MA)
o apex-Qe
o autoflex II, autoflex II TOF/TOF
o ClinProt Large-Protein Beads
o ClinProt Micro
o ClinProtRobot
o Isotope Coded Protein Labels (ICPL) Triplex Kit
o MALDI Molecular Imager
o microflex, microflex LT
o Protein Post-Translational Modification (PTM) Discovery Tool
o ultraflex, ultraflex TOF/TOF
o Expression Pathology (Gaithersburg, MD)
o Liquid Tissue MS Protein Prep Kit
o PerkinElmer (Wellesley, MA)
o prOTOF 2000 MALDI O-TOF
o Qiagen (Venlo, The Netherlands)
o MSXpress Protein Chip
o Shimadzu / Kratos (Kyoto, Japan)
o LCMS-IT-TOF
o Thermo Electron (Waltham, MA)
o LTQ XL
o LTQ FT
o LTQ Orbitrap
o MDLC LTQ LC-MS
o Waters (Milford, MA)
o LCT Premier XE
o micro MX
o Protein Expression System
o Q-Tof Premier
* Total Market Size and Growth Forecast
* The Market by Disease Area
* Competitive Analysis: Market Share by Vendor
* Market Share by Product Type
Chapter Nine: Consortia and Alliances
* The Biomarker Alliance
* Biomarkers Research Initiatives in Mass Spectrometry (BRIMS)
* Clinical Proteomic Technologies Initiative for Cancer
* Clinical Plasma Profiling Consortium
* Early Detection Research Network (EDRN)
* HUPO Plasma Proteome Project
* Oncology Biomarker Qualification Initiative (OBQI)
* Pharmacogenomics Research Network (PGRN)
* Predictive Safety Testing Consortium
Chapter Ten: Company Profiles
* Agilent Technologies (Palo Alto, CA)
* Applied Biosystems / MDS Sciex (Foster City, CA ; Ontario, Canada)
* Bruker BioSciences (Billerica, MA)
* Ciphergen Biosystems (Fremont, CA) (Bio-Rad)
* GE Healthcare Bio-Sciences (Little Chalfont, United Kingdom) -
* formerly Amersham Biosciences (Uppsala, Sweden)
* PerkinElmer (Wellesley, MA)
* Thermo Electron (Waltham, MA)
* Waters (Milford, MA)
Chapter Eleven: Deals
Chapter Twelve: Academic / Government / Non-Profit Research
* The Center for Biomarker Research
* Johns Hopkins Center for Biomarker Discovery
* Plasma Proteome Institute
Chapter Thirteen: Competitive or Disruptive Technologies
* Protein Arrays, Chips
o Invitrogen ProtoArray
o Protneteomix Protein, Peptide and Antibody Arrays
o Whatman Schleicher & Schuell Serum Biomarker Chip
o Array of Micromachined Ultra Sonic Electrospray (AMUSE)
o Monogram Biosciences’ (formerly Aclara) eTag Technology
o Imaging-Based Techniques
o ELISA
Chapter Fourteen: Challenges
* Debate Over Serum Proteomics and Biomarkers
* Advances in Competing, Complementary Techniques, Software Erode Sales
* Reproducibility is Key Priority But Elusive
* Clinical Research Not Yet Experienced With Biomarkers, Procedures
* Blockbuster Mentality Creates Obstacles for Biomarkers
* Gap Between Pharmaceuticals and Diagnostics Still Wide
* Large Investment Required for Biomarker Validation Creates Gap
* Dropping Prices Hurt Revenues, Confuse Customers
* Regulatory and Ethical Issues Not Completely Resolved
* Feasibility of Biomarker Approaches Still Unproven
* Data Analysis Bottleneck Slows Momentum
Chapter Fifteen: Strategic Recommendations
* Recommendation 1: Software
* Recommendation 2: Consumables
* Recommendation 3: Standards, Quality, and Data Exchange
* Recommendation 4: Reliability and User-Friendliness
* Recommendation 5: Systems Biology
* Recommendation 6: Partnering for Novel Technologies
* Recommendation 7: Drug and Diagnostics Partnerships
* Recommendation 8: Training and Education
List of Exhibits
Chapter One: Executive Summary
* Figure 1-1: Market Summary: MS for Protein Biomarker Applications 2005-2011
Chapter Six: MS Software Market
* Table 6-1: The World Market for Protein Biomarker MS Software (Revenues) 2005-2011
* Figure 6-1: Trending in the Revenues for Protein Biomarker MS Software 2005-2011
* Table 6-2: The World Market for Protein Biomarker MS Software (Growth) 2005-2011
* Figure 6-2: Trending in the Growth of Protein Biomarker MS Software 2005-2011
Chapter Seven: MS Services Market
* Table 7-1: The World Market for Protein Biomarker Services (Revenues) 2005-2011
* Figure 7-1: Trending in the Revenues for Protein Biomarker Services 2005-2011
* Table 7-2: The World Market for Protein Biomarker Services (Growth) 2006-2011
* Figure 7-2: Trending in the Growth of Protein Biomarker Services 2006-2011
Chapter Eight: MS Instrumentation Market
* Table 8-1: The World Market for MS Instruments for Protein Biomarker Applications (Revenues) 2005-2011
* Figure 8-1: Trending in the Revenues for MS Instruments for Protein Biomarker Applications 2005-2011
* Table 8-2: The World Market for MS Instruments for Protein Biomarker Applications (Growth) 2006-2011
* Figure 8-2: Trending in the Growth of MS Instruments for Protein Biomarker Applications 2006-2011
* Table 8-3: Protein Biomarker MS Revenues and Market Share by Disease Area 2005
* Figure 8-3: Protein Biomarker MS Market Share by Disease Area 2005
* Table 8-4: Protein Biomarker MS Revenues and Market Share by Leading Supplier 2005
* Figure 8-4: Protein Biomarker MS Market Share by Leading Supplier 2005
* Table 8-5: Protein Biomarker MS Revenues and Market Share by Product Type (Ion Trap, MALDI-TOF, Triple Quad, QqTOF, FTMS, Other, Service/Support) 2005
* Figure 8-5: Protein Biomarker MS Market Share by Product Type 2005
Chapter Nine: Consortia and Alliances
* Table 9-1: Early Detection Research Network (EDRN) Awardees (Institution, Organ Focus, Technology/Approach, Industry Collaboration)
Chapter Eleven: Deals
* Table 11-1: Recent Deals, Collaborations, and Alliances